NEW YORK (GenomeWeb) – Roche said this week that its Ventana PD-L1 assay has been expanded for use in non-small cell lung cancer and metastatic urothelial carcinoma in countries that recognize CE marking, and where Roche's Tecentriq cancer immunotherapy is approved. The assay was previously approved by the US Food and Drug Administration as a complementary diagnostic for assessing patients with NSCLC and mUC being considered for treatment with Tecentriq. It uses immune cell and tumor cell staining within the tumor microenvironment to evaluate patients with PD-L1 status.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

What happens to scientific papers when certain journals are no longer published? Some scientists are trying to make sure they don't disappear forever.

A study in Microbiome finds that heavy drinkers have an unhealthy mix of bacteria in their mouths.

Doctors and patients are still trying to figure out what role at-home genetic testing should play in healthcare, Newsweek says.

In Genome Research this week, mismatch repair deficiency in C. elegans, retracing transcriptions start site evolution in the human genome, and more.